Aurinia Pharmaceuticals Selects MyMeds&Me’s QuickStart Platform to Streamline Reporting
MyMeds&Me today announced that Aurinia Pharmaceuticals Inc. has selected the Reportum QuickStart platform to streamline the capture, processing, and management of safety data for the investigational drug voclosporin following recent positive Phase III results.
Aurinia will implement the Reportum QuickStart platform to support the launch of voclosporin, enabling adverse event, product quality complaint, and medical information requests to be captured by field-based representatives, medical science liaisons, and speciality pharmacy providers, as well as direct from healthcare professionals and consumers.
Offering the full safety data-capture functionality of the Reportum platform, QuickStart is a preconfigured and validated solution to facilitate rapid set-up and cost-effective deployment. QuickStart enables pharmacovigilance teams of all sizes to benefit from a robust and scalable drug safety system that can be implemented within a matter of weeks.
For more information, click here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
